08:27 AM EDT, 09/25/2025 (MT Newswires) -- MediWound ( MDWD ) said Thursday that Australia's Therapeutic Goods Administration has granted a marketing authorization to the company's NexoBrid.

The company said its exclusive partner in Australia expects a commercial launch of NexoBrid in Q4.

MediWound ( MDWD ) further said that its manufacturing expansion is on track for completion by the end of the year.

NexoBrid is an enzymatic therapy for the removal of eschar or dead tissue crust in both adult and pediatric patients with deep partial and full-thickness thermal burns, the company said.